MedPath

Cell-Based Noninvasive Prenatal Testing

Not Applicable
Recruiting
Conditions
Pregnancy Related
Registration Number
NCT05245266
Lead Sponsor
Luna Genetics
Brief Summary

The purpose of the overall study is to develop improved methods for recovery and analysis of fetal cells from the mother's blood in order to develop clinically useful forms of cell-based, diagnostic, noninvasive prenatal testing (NIPT). Luna genetics will obtain and analyze research blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood samples. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of fetal cells recovered and quality of DNA data on each cell3 years

Outcome measure 2 is the number of cells that yield high quality next generation

sequencing data suitable for determining copy number across the entire genome. So if 4 of the 8 cells above gave high quality data, the outcome would be 4 cells with high quality copy number data from one blood draw which equals 0.10 high quality cell / mL of mother's b

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Luna Genetics

🇺🇸

Houston, Texas, United States

Luna Genetics
🇺🇸Houston, Texas, United States
Arthur Beaudet, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.